Orrego H, Kalant H, Israel Y, Blake J, Medline A, Rankin J G, Armstrong A, Kapur B
Gastroenterology. 1979 Jan;76(1):105-15.
The effect of propylthiouracil (PTU; 300 mg/day) on alcoholic liver disease was evaluated in 133 patients in a short-term randomized double-blind trial. Severity of the disease was assessed by a composite clinical and laboratory index (CCLI). A normalization rate (NR) representing the rate of improvement in CCLI was calculated. Patients with alcoholic hepatitis, with and without cirrhosis, showed a significantly higher NR on PTU (43.6 +/- 4.6) than on placebo (19.8 +/- 3.3; P less than 0.001). A similar effect was observed in patients with abnormal prothrombin (no biopsy): NR was 32.9 +/- 6.9 on PTU and 2.6 +/- 3.7 on placebo (P less than 0.005). The effect of PTU on each clinical and laboratory component of the CCLI was also compared in these two groups. In 38 patients with alcoholic hepatitis and in 25 with abnormal prothrombin, those on PTU showed a greater improvement in 15 of 15 items (P less than 0.001) and 14 of 15 (P less than 0.01), respectively. When patients were divided according to the severity of the disease into those in the lower and upper halves of the CCLI range (81 and 52 patients, respectively), PTU was shown to have a significant effect only in the latter: The NR was 41.4 +/- 3.8 on PTU and 22.5 +/- 4.2 on placebo (P less than 0.005). PTU was ineffective in patients with inactive cirrhosis.
在一项短期随机双盲试验中，对133例患者评估了丙硫氧嘧啶（PTU；300毫克/天）对酒精性肝病的影响。通过综合临床和实验室指标（CCLI）评估疾病的严重程度。计算了代表CCLI改善率的正常化率（NR）。患有酒精性肝炎（无论有无肝硬化）的患者，PTU组的NR（43.6±4.6）显著高于安慰剂组（19.8±3.3；P<0.001）。在凝血酶原异常（未进行活检）的患者中也观察到了类似的效果：PTU组的NR为32.9±6.9，安慰剂组为2.6±3.7（P<0.005）。还比较了PTU对这两组患者CCLI各临床和实验室指标的影响。在38例酒精性肝炎患者和25例凝血酶原异常患者中，PTU组在15项指标中的15项（P<0.001）和15项中的14项（P<0.01）分别显示出更大的改善。当根据疾病严重程度将患者分为CCLI范围下半部分和上半部分的患者（分别为81例和52例）时，PTU仅对后者有显著效果：PTU组的NR为41.4±3.8，安慰剂组为22.5±4.2（P<0.005）。PTU对静止性肝硬化患者无效。
